{"analyses":[{"ciLowerLimit":"0.83","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.33","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6906","paramType":"Odds Ratio (OR)","paramValue":"1.05","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"4.2","value":"2.9"},{"groupId":"OG001","lowerLimit":"2.7","upperLimit":"4.1","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"247"}],"units":"Participants"}],"description":"PFS was defined as the time from study start to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first). PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. PFS was analyzed using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg"},{"description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized participants, with participants grouped according to their assigned treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 25 months","title":"Part 2: Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}